<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
< Back to all Breaking News
TTWO, ACCD, RKLY...
9/17/2021 09:09am
Take-Two downgrade among today's top calls on Wall Street

Check out today's top analyst calls from around Wall Street, compiled by The Fly.

'DISCONCERTING TREND': BMO Capital analyst Gerrick Johnson downgraded Take-Two Interactive (TTWO) to Market Perform from Outperform with a price target of $150, down from $225. The analyst is less confident in his previously high on the Street earnings estimates after a after a series of video game release delays, which he calls a "disconcerting trend." Johnson expects Take-Two's valuation multiple to remain under pressure, owning to "exogenous events" such as new Chinese gaming regulations and closer scrutiny of video games companies, including content in Grand Theft Auto, amid a heightened environmental, social and governance focus among institutional investors.

EXECUTION, VALUATION DISCOUNT: Baird analyst Vikram Kesavabhotla upgraded Accolade (ACCD) to Outperform from Neutral with a price target of $54, down from $58. The company is positioned for a potential upward estimate revision cycle and catalyst opportunities that could present incremental upside, Kesavabhotla tells investors in a research note. The analyst is "incrementally constructive" after talking with management and says the shares are trading at a discount to peers. Accolade's "profile for execution" will be viewed favorably in the context of uncertainty across the broader sector, contends Kesavabhotla.

BUY ROCKLEY PHOTONICS: BofA analyst Vivek Arya initiated coverage of Rockley Photonics (RKLY) with a Buy rating and $14 price target. The company's optical sensing platform targets a $32B total addressable market in the monitoring of critical biomarkers via smart wearable devices, Arya tells investors in a research note. The analyst says that unlike traditional LED solutions, Rockley's integrated spectrophotometer and on-device analytics platform offers "much higher" resolution and accuracy, enabling healthcare clinic-on-the-wrist solution to monitor glucose and lactate levels, blood alcohol, core body temp, hydration and alcohol levels.

EV DEMAND STORY STARTING TO PLAY OUT: Wedbush analyst Daniel Ives keeps an Outperform rating and $1,000 price target on Tesla (TSLA), tells investors in a research note that he believes the Tesla EV demand story is just starting to play out despite some lingering China headwinds which are starting to reverse course heading into the end of the year. The analyst believes Tesla can near 900,000 annual deliveries this year and track towards 1.3M next year.

FACEBOOK PRICE TARGET RAISED: Jefferies analyst Brent Thill raised the firm's price target on Facebook (FB) to $440 from $425 and keeps a Buy rating on the shares as he rolls forward his estimates. He notes the stock has outperformed the Nasdaq year-to-date, but he still views the valuation as "compelling" and thinks the company's revenue guidance for the second half of the year appears "conservative," adding that Facebook has beaten Street revenue forecasts for the last 11 quarters. Instagram Reels and Shops ads should be incremental upside drivers for 2022 sales growth, added Thill.

dynamic_feed Breaking News